NCT02216656View on ClinicalTrials.gov

Phase 2 Study of KHK7580

PHASE2CompletedINTERVENTIONAL

Enrollment

201

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

February 28, 2015

Study Completion Date

February 28, 2015

Conditions

Secondary Hyperparathyroidism

Interventions

DRUG

Placebo

Oral administration

DRUG

KHK7580 low dose

Oral administration

DRUG

KHK7580 middle dose

Oral administration

DRUG

KHK7580 high dose

Oral administration

DRUG

KRN1493

Oral administration

Trial Locations (1)

Unknown

For additional information regarding investigative sites for this trial, contact Kyowa Hakko Kirin, Tokyo

All Listed Sponsors

lead

Kyowa Kirin Co., Ltd.

INDUSTRY

NCT02216656 - Phase 2 Study of KHK7580 | Biotech Hunter | Biotech Hunter